KRAS and familial pancreatic carcinoma: Deng et al. fused CLT (Celastrol)-loaded PEGylated lipids with DC2.4 cell membranes (M-LIP-CLT) to construct a delivery system targeting Kras-mutated pancreatic cancer [92].